2019
DOI: 10.1111/ijlh.13014
|View full text |Cite
|
Sign up to set email alerts
|

Molecular diagnostic update in hereditary hemolytic anemia and neonatal hyperbilirubinemia

Abstract: Hereditary hemolytic anemia (HHA) is a group of genetically and phenotypically heterogeneous disorders characterized by premature destruction of red blood cells (RBCs) with clinical manifestations ranging from asymptomatic to marked hemolytic anemia. There are three main categories of HHA: (a) RBC membrane defects; (b) hemoglobinopathies/thalassemias; and (c) RBC enzyme deficiencies. Hyperbilirubinemia is a frequent consequence of hemolytic anemia and can lead to bilirubin‐associated neurotoxicity in neonates … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
28
0
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
1
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 40 publications
(31 citation statements)
references
References 47 publications
2
28
0
1
Order By: Relevance
“…Recommendations proposed by King et al in 2015 [13], and compiled by Kim et al in 2017 [74] concerning the indications of genetic testing for CHA diagnosis need to be updated, as they only recommended genetic testing in a limited number of cases and as a second diagnostic step. A recent article of Rets et al in 2019 suggests that targeted NGS becomes the diagnosis standard tool in CHA molecular testing and that WES and WGS could represents the future [75]. Our results show that molecular diagnosis with WES could easily be democratized and be of great help to understand patients' phenotype, adapting therapeutic approach (such as splenectomy) and to allow genetic counseling.…”
Section: Discussionmentioning
confidence: 58%
“…Recommendations proposed by King et al in 2015 [13], and compiled by Kim et al in 2017 [74] concerning the indications of genetic testing for CHA diagnosis need to be updated, as they only recommended genetic testing in a limited number of cases and as a second diagnostic step. A recent article of Rets et al in 2019 suggests that targeted NGS becomes the diagnosis standard tool in CHA molecular testing and that WES and WGS could represents the future [75]. Our results show that molecular diagnosis with WES could easily be democratized and be of great help to understand patients' phenotype, adapting therapeutic approach (such as splenectomy) and to allow genetic counseling.…”
Section: Discussionmentioning
confidence: 58%
“…Regarding our results, exome sequencing in the field of CHA appears as highly performant, in HS but also in UH.Recommendations proposed by King et al in 2015[13], and compiled by Kim et al in 2017[64] concerning genetic testing for CHA diagnosis need to be updated, as they only recommended genetic testing in a limited number of cases as a second diagnostic step. A recent article of Rets et al in 2019 suggests that targeted NGS becomes the diagnosis standard tool in CHA molecular testing and that WES and WGS could represents the future[65]. Our results show that molecular diagnosis with WES could easily be democratized and is fundamental for understanding patients' phenotype, adapting therapeutic approach (such as splenectomy) and permiting genetic counseling.…”
mentioning
confidence: 59%
“…The functional tests are therefore crucial to assess the pathogenicity of new variants detected by NGS. Moreover, further problems can arise from the need for adequate coverage of the genes when there are copy number variants and GC−rich regions with low−complexity (Rets et al, 2019). Currently, a targeted-NGS approach is preferred in the diagnostic work-up for these disorders (Agarwal et al, 2016;Del Orbe Barreto et al, 2016;Niss et al, 2016;Roy et al, 2016;Russo et al, 2018;Choi et al, 2019;Kedar et al, 2019;Svidnicki et al, 2020).…”
Section: Second-generation Sequencing: Ngs Short Readsmentioning
confidence: 99%